Hill Country Authors – Exploring the Challenges of a Green Transition with Tom Ortiz
Daily Compliance News: August 5, 2025, The Staying Focused Edition
Daily Compliance News: August 1, 2025, The All AI Edition
Daily Compliance News: July 31, 2025 the Forgotten Generation Edition
Just Press "Play"
Everything Compliance: Shout Outs and Rants: Episode 158, No To Ukraine Corruption
Daily Compliance News: July 29, 2025 the Is CEO Conduct Ever Personal Edition
Daily Compliance News: July 25, 2025, The New Sheriff in Town Edition
Daily Compliance News: July 23, 2025 the Pardon in the Wind? Edition
Daily Compliance News: July 22, 2025, The I-9 Hell Edition
10 For 10: Top Compliance Stories For the Week Ending July 19, 2025
Sittenfeld v. United States – Campaign Contributions as Crimes?
Podcast - Walking Tall
Podcast - The Seeds of Corruption
The Dark Patterns Behind Corporate Scandals
10 For 10: Top Compliance Stories For the Week Ending June 21, 2025
Daily Compliance News: June 19, 2025, The Corruption in Spain Edition
Daily Compliance News: June 9, 2025, The Repugnant Edition
10 For 10: Top Compliance Stories For the Week Ending June 7, 2025
On January 14, 2025, China issued the final version of its compliance guidelines for health care companies to prevent commercial bribery risks (“Guidelines”), which took effect immediately. The Guidelines are applicable to...more
Like many companies in other sectors, Life Sciences companies recognize that corporate social responsibility (CSR)–evaluated and measured by independent rating organizations and based on their compliance with any applicable...more
I have written extensively about the Novartis International AG (Novartis) Foreign Corrupt Practices Act (FCPA) settlement, which was announced in late June. However, the enforcement action paled next to the Stipulation and...more
Novartis Pharmaceuticals Corporation (Novartis) has started July with significant settlements, putting two different fraud and abuse matters behind them. In what has been identified as the largest settlement of an...more
This blog post will close my review of the Foreign Corrupt Practices Act (FCPA) enforcement action involving the Swiss pharmaceutical company Novartis AG, its Greek subsidiary Novartis Hellas S.A.C.I. (Novartis Greece) and...more
This week I am reviewing the Foreign Corrupt Practices Act (FCPA) enforcement action involving the Swiss pharmaceutical company Novartis AG, its Greek subsidiary Novartis Hellas S.A.C.I. (Novartis Greece) and Alcon Pte Ltd.,...more
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC enforcement action in China. Given Novartis weak culture of compliance (if anything, a better description may be a culture of...more
Novartis and Alcon engaged in separate but significant bribery schemes. Considering the fact that Novartis had a similar violation in 2016 in China involving much of the same conduct, Novartis’ conduct reflects a weak...more
The Justice Department and the FBI have quickly acted to focus on fraudsters and hoarders seeking to profit from the public panic in response to the pandemic. DOJ issued a memo to U.S. Attorneys prioritizing investigations...more
On October 1, 2019, in In re Clovis Oncology, Inc. Derivative Litigation, a Delaware Chancery Court denied a motion to dismiss the plaintiffs’ claims under the Caremark decision against individual directors for failing to...more
In this hoganlovells.com interview, Hogan Lovells partner Gejaa Gobena discusses how the perception of compliance, remediation, and self-disclosure has evolved in the eyes of government prosecutors from how they factor at...more